# OnCo record paper-robin-jones-lancet-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-robin-jones-lancet-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-robin-jones-lancet-2016" ;
  schema:name "Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial"@en ;
  schema:description "Paper by Robin L. Jones indexed on Europe PMC as PubMed record 27291997, in The Lancet (2016), one of the most cited records naming an author with this name at The Royal Marsden."@en ;
  schema:url <https://onco.cc/key-papers/paper-robin-jones-lancet-2016/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(16)30587-6>, <https://pubmed.ncbi.nlm.nih.gov/27291997/>, <https://europepmc.org/article/MED/27291997> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(16)30587-6> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Tap WD, Jones RL, Van Tine BA, et al." ;
  onco:people <https://onco.cc/people/robin-jones/> ;
  onco:journals <https://onco.cc/journals/lancet/> .